Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06857864

Exploratory Study on the Effectiveness of Myopia Control Lenses in Slowing Myopia Progression in Young Children

Status
Active Not Recruiting
Phase
N/A
Study type
Interventional
Enrollment
25 (estimated)
Sponsor
Essilor International · Industry
Sex
All
Age
6 Years – 8 Years
Healthy volunteers
Accepted

Summary

This study will be a mono-center, single-arm, unmasked study evaluating the effectiveness of test lens in slowing myopia progression in children aged 6 to 8 years. The study aims to evaluate the change in axial elongation and spherical equivalent refraction in younger children who are fitted with the test lens over a 1-year period. A total of 25 children will be recruited.

Detailed description

As myopia has become a global epidemic and public health concern, it is crucial to gain deeper insight to the possible treatments in slowing myopia progression. In a previous clinical trial, spectacle lenses with higher lenlets asphericity demonstrated effectiveness in reducing myopia progression and axial length elongation in children. This clinical trial will assess the effectiveness of a test lens in slowing myopia progression in younger children over 1 year. Without compromising vision, the test lens is designed to modify the area and the amount of myopia defocus on the retina. The study population includes 25 children subjects in Singapore, aged 6 to 8 years during the commencement of the treatment. The axial length and spherical equivalent refraction will be the primary and secondary measures for myopia progression.

Conditions

Interventions

TypeNameDescription
DEVICETest myopia control lenses (BSL)Test spectacle lenses will be provided to the subjects throughout the 1 year clinical trial.

Timeline

Start date
2025-03-17
Primary completion
2026-07-01
Completion
2026-07-01
First posted
2025-03-04
Last updated
2025-07-20

Locations

1 site across 1 country: Singapore

Source: ClinicalTrials.gov record NCT06857864. Inclusion in this directory is not an endorsement.